Zalman Starosta
Internal Medicine · Brooklyn, NYNPI 1013900513
Payments from drug & device makers
Across 366 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amarin Pharma, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$849
- AbbVie$790
- Amgen$560
- Astellas Pharma US Inc$374
- plus $2K from 32 others
What the payments were for
- Food & beverage$7,08997%
- Education$2423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,331 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lactulose | 12 | $74,235 |
| MounjaroTirzepatide | 22 | $21,721 |
| Zileuton ErZileuton | 13 | $19,212 |
| OzempicSemaglutide | 20 | $19,073 |
| VascepaIcosapent Ethyl | 33 | $13,455 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $13,429 |
| JubliaEfinaconazole | 11 | $12,445 |
| LinzessLinaclotide | 22 | $12,260 |
| EliquisApixaban | 20 | $12,139 |
| Metformin Er GastricMetformin Hcl | 26 | $9,463 |
| Repatha SureclickEvolocumab | 15 | $8,730 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,983 |
| Praluent PenAlirocumab | 15 | $7,937 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,733 |
| JardianceEmpagliflozin | 13 | $7,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $97 | $21,72122 claims |
| Novo NordiskOzempic | $244 | $19,07320 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance | $41 | $15,35027 claims |
| AbbVieLinzess, Synthroid | $790 | $13,58450 claims |
| PfizerEliquis | $196 | $12,13920 claims |
| GSKBreo Ellipta | $24 | $5,97314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Brooklyn
- Bruce BergerBrooklyn$3.4M
- Nelly CohenBrooklyn$2.8M
- Jorge SerjeBrooklyn$1.3M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.